To this end, destroying a fine-tuned antioxidant system with specific inhibitors or inducing excessive levels of ROS beyond the antioxidant capacity of cancer cells could be attractive strategies for cancer therapy.144 However, although ROS inducers have been reported to be effective in several cases, drug resistance still seems to occur.17 For example, it has been reported that daunomycin/AraC treatment contributes to the upregulation of P-glycoprotein (P-gp) in acute myeloid leukemia (AML) patients. Here, ABCB1 is linked to acute myeloid leukemia.